Search Result

Results for "

JAK2 and FLT3 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FLT3 (26) Akt (2) Anaplastic lymphoma kinase (ALK) (2) Apoptosis (12) Aurora Kinase (3) Autophagy (4) Bcr-Abl (4) CDK (4) EGFR (1) FGFR (1) Isotope-Labeled Compounds (1) JAK (26) mTOR (2) PI3K (2) Reference Standards (1) RET (3) STAT (3) Syk (2) TGF-beta/Smad (2) TGF-β Receptor (2) Trk Receptor (1) VEGFR (1)
By Research Areas:	Cancer (27) Cardiovascular Disease (1) Inflammation/Immunology (4)

Inhibitors & Agonists

Isotope-Labeled Compounds

Targets Recommended: FLT3 Fat Mass and Obesity-associated Protein (FTO)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-130247

Flonoltinib 1 Publications Verification JAK2/FLT3-IN-1	JAK FLT3 Apoptosis	Cancer
Flonoltinib is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib has anti-cancer activity .

HY-130247A

Flonoltinib TFA 1 Publications Verification JAK2/FLT3-IN-1 TFA	JAK FLT3 Apoptosis	Cancer
Flonoltinib TFA is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib TFA has anti-cancer activity .

HY-15166B

(E/Z)-Zotiraciclib citrate 5+ Cited Publications (E/Z)-TG02 citrate; (E/Z)-SB1317 citrate	CDK JAK FLT3	Cancer
(E/Z)-Zotiraciclib citrate is a potent CDK2, *JAK2, and FLT3* inhibitor .

HY-16379

Pacritinib Maximum Cited Publications 18 Publications Verification SB1518	JAK FLT3	Cancer
Pacritinib (SB1518) is a potent inhibitor of both wild-type *JAK2* (IC₅₀=23 nM) and JAK2 ^V617F mutant (IC₅₀=19 nM). Pacritinib also inhibits *FLT3* (IC₅₀=22 nM) and its mutant FLT3 ^D835Y (IC₅₀=6 nM).

HY-10410

TG101209 5 Publications Verification	FLT3 JAK RET Autophagy Apoptosis	Cancer
TG101209 is a selective *JAK2* inhibitor with IC₅₀ of 6 nM, less potent to *Flt3* and RET with IC₅₀ of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.

HY-161967

JAK2/FLT3-IN-3	FLT3 JAK Apoptosis	Cancer
JAK2/FLT3-IN-3 (11r) is a dual *FLT3* and *JAK2* inhibitor, with IC₅₀ values of 2.01 nM, 0.51 nM and 104.40 nM for JAK2, FLT3 and JAK3, respectively. JAK2/FLT3-IN-3 (11r) induces apoptosis and possesses antitumor activity .

HY-130247B

Flonoltinib monomaleate JAK2/FLT3-IN-1 monomaleate	JAK FLT3 Apoptosis	Cancer
Flonoltinib maleate is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 has anti-cancer activity .

HY-16449

SB1578 CT-1578	JAK FLT3	Inflammation/Immunology
SB1578 (CT-1578) is a selective *JAK2* and *FLT3* inhibitor with an IC₅₀ of 46 nM and 60 nM, respectively. SB1578 exhibits high selectivity for other kinase targets. SB1578 can be used for the study of non-oncology indication rheumatoid arthritis .

HY-130247C

Flonoltinib sulfate JAK2/FLT3-IN-1 sulfate	JAK FLT3 Apoptosis	Cancer
Flonoltinib maleate is a potent and orally active dual *JAK2/FLT3* inhibitor with IC₅₀ values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib maleate has anti-cancer activity .

HY-16379A

Pacritinib hydrochloride SB1518 hydrochloride	JAK FLT3	Cancer
Pacritinib hydrochloride is a potent inhibitor of both wild-type *JAK2* (IC₅₀=23 nM) and JAK2 ^V617F mutant (IC₅₀=19 nM). Pacritinib hydrochloride also inhibits *FLT3* (IC₅₀=22 nM) and its mutant FLT3 ^D835Y (IC₅₀=6 nM). Pacritinib hydrochloride can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF) .

HY-16379S

Pacritinib-d4 SB1518-d₄	Isotope-Labeled Compounds JAK FLT3	Cancer
Pacritinib-d₈ (SB1518-d₈) is the deuterium labeled Pacritinib (HY-16379). Pacritinib (SB1518) is a potent inhibitor of both wild-type *JAK2* (IC₅₀=23 nM) and JAK2 ^V617F mutant (IC₅₀=19 nM). Pacritinib also inhibits *FLT3* (IC₅₀=22 nM) and its mutant FLT3 ^D835Y (IC₅₀=6 nM).

HY-16379B

Pacritinib citrate Maximum Cited Publications 18 Publications Verification SB1518 citrate	JAK FLT3	Cancer
Pacritinib (SB1518) citrate is a potent inhibitor of both wild-type *JAK2* (IC₅₀=23 nM) and JAK2 ^V617F mutant (IC₅₀=19 nM). Pacritinib citrate also inhibits *FLT3* (IC₅₀=22 nM) and its mutant FLT3 ^D835Y (IC₅₀=6 nM). Pacritinib citrate can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF) .

HY-118084

LS-104 Tyrene CR-4	JAK Bcr-Abl FLT3 Apoptosis	Cardiovascular Disease Inflammation/Immunology Cancer
LS-104 (Tyrene CR-4) is a non-ATP-competitive kinase inhibitor against *JAK2, Bcr-Abl* and *FLT3. LS-104 potently induces apoptosis* in JAK2V617F-positive cells and inhibits *JAK2* autophosphorylation and downstream signal transduction. LS-104 also inhibits proliferation and induces potent cytotoxic effects in FLT3 expressing leukemic cells. LS-104 is a hydroxystyryl-acrylonitrile compound, which is promising for research of myeloproliferative disorders and refractory/relapsed hematologic malignancies .

HY-131906

JAK2-IN-7	JAK FLT3 Apoptosis	Cancer
JAK2-IN-7 is a selective *JAK2* inhibitor with IC₅₀s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3 ^V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities .

HY-109179A

Itacnosertib hydrochloride TP-0184 hydrochloride	JAK Anaplastic lymphoma kinase (ALK) FLT3 STAT PI3K Akt mTOR TGF-beta/Smad TGF-β Receptor	Cancer
Itacnosertib hydrochloride (TP-0184 hydrochloride) is the inhibitor for *FLT3, ACVR1* (ALK2, IC₅₀=8 nM) and *JAK2* (IC₅₀=8540 nM). Itacnosertib hydrochloride exhibits anti-leukemic activity .

HY-109179

Itacnosertib TP-0184	JAK Anaplastic lymphoma kinase (ALK) FLT3 STAT PI3K Akt mTOR TGF-beta/Smad TGF-β Receptor	Cancer
Itacnosertib (TP-0184) is the inhibitor for *FLT3, ACVR1* (ALK2, IC₅₀=8 nM) and *JAK2* (IC₅₀=8540 nM). Itacnosertib exhibits anti-leukemic activity .

HY-13034

Gandotinib 3 Publications Verification LY2784544	JAK FLT3 FGFR VEGFR	Cancer
Gandotinib (LY2784544) is a potent *JAK2* inhibitor with IC₅₀ of 3 nM. Gandotinib (LY2784544) also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with IC₅₀ of 4, 25, 32, 44, and 95 nM.

HY-15163

Zotiraciclib 1 Publications Verification TG02; SB1317	JAK CDK FLT3	Cancer
Zotiraciclib (TG02) is an orally active potent inhibitor of CDK2, *JAK2* and *FLT3* with IC₅₀ values of 13, 73, and 56 nM, respectively. Zotiraciclib can be used for the research of advanced leukemias and multiple myeloma .

HY-15166

(E/Z)-Zotiraciclib 5+ Cited Publications (E/Z)-TG02; (E/Z)-SB1317	CDK JAK FLT3	Cancer
(E/Z)-Zotiraciclib ((E/Z)-TG02) is a potent inhibitor of CDK2, *JAK2* and *FLT3* with IC₅₀s of 13, 73 and 56 nM, respectively. (E/Z)-Zotiraciclib effectively inhibits the proliferation of cancer cells, it can be used for the research of cancer .

HY-15166A

(E/Z)-Zotiraciclib hydrochloride 5+ Cited Publications (E/Z)-TG02 hydrochloride; (E/Z)-SB1317 hydrochloride	CDK JAK FLT3	Cancer
(E/Z)-Zotiraciclib ((E/Z)-TG02) is an orally active inhibitor of CDK2, *JAK2* and *FLT3* with IC₅₀s of 13, 73 and 56 nM, respectively. (E/Z)-Zotiraciclib effectively inhibits the proliferation of cancer cells, it can be used for the research of cancer .

HY-16379R

Pacritinib (Standard) SB1518 (Standard)	Reference Standards JAK FLT3	Cancer
Pacritinib (Standard) is the analytical standard of Pacritinib. This product is intended for research and analytical applications. Pacritinib (SB1518) is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM). Pacritinib also inhibits FLT3 (IC50=22 nM) and its mutant FLT3D835Y (IC50=6 nM).

HY-50514

AT9283 5+ Cited Publications	JAK Aurora Kinase Bcr-Abl FLT3 Apoptosis Autophagy	Cancer
AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, *JAK2/3, Abl (T315I)* and *Flt3* (IC₅₀s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo .

HY-10058

AT9283 lactic acid	JAK Aurora Kinase Bcr-Abl FLT3 Apoptosis Autophagy	Cancer
AT9283 lactic acid is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, *JAK2/3, Abl (T315I)* and *Flt3* (IC₅₀s ranging from 1 to 30 nM). AT9283 lactic acid inhibits growth and survival of multiple solid tumors in vitro and in vivo .

HY-125051

SG3-179	JAK FLT3	Cancer
SG3-179 is a potent inhibitor against the BET bromodomain proteins. SG3-179 is also a *JAK2* and *FLT3* inhibitor. SG3-179 causes a rapid reduction in HOXB13 protein expression. SG3-179 is promising for research of multiple myeloma (MM1.S) .

HY-50514R

AT9283 (Standard)	JAK Aurora Kinase Bcr-Abl FLT3 Apoptosis Autophagy	Cancer
AT9283 (Standard) is the analytical standard of AT9283. This product is intended for research and analytical applications. AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC50s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo .

HY-50867

Lestaurtinib 3 Publications Verification CEP-701; KT-5555	JAK FLT3 Trk Receptor Apoptosis STAT	Cancer
Lestaurtinib (CEP-701) is an orally active and selective RPTKs (receptor protein tyrosine kinase) inhibitor, competitively inhibits ATP binding to the TrkA/B/C domain. Lestaurtinib inhibits RPTKs phosphorylation, with IC₅₀s of 2, 25 and 0.9 nM for *FLT3, TrkA* and *JAK2, respectively. Lestaurtinib induces apoptosis* and cycle arrest, also can inhibit growth of tumor .

HY-120214

TAS05567	Syk RET	Inflammation/Immunology
TAS05567 is a potent, highly selective, ATP-competitive and orally active Syk inhibitor with an IC₅₀ of 0.37 nM. In a panel of 192 kinases, TAS05567 only shows >70% inhibition of Syk and 4 other kinases (FLT3, JAK2, KDR and RET with IC₅₀s of 10 nM, 4.8 nM, 600 nM and 29 nM, respectively). TAS05567 can be used for humoral immune-mediated inflammatory conditions such as autoimmune and allergic diseases .

HY-132193

RET-IN-4	RET	Cancer
RET-IN-4 is a potent, selective and orally active RET inhibitor with IC₅₀s of 1.29 nM, 1.97 nM, and 0.99 nM for RET (WT), RET (V804M), and RET (M918T), respectively. RET-IN-4 exhibits better kinases selectivity against JAK2 (IC₅₀ of 4.4 nM) and FLT3 (IC₅₀ of 30.8 nM). RET-IN-4 has anticancer effects .

HY-109082

Cevidoplenib SKI-O-703	Syk	Inflammation/Immunology
Cevidoplenib (SKI-O-703) is an orally available inhibitor of spleen tyrosine kinase (Syk), with potential anti-inflammatory and immunomodulating activities. Cevidoplenib is also the mesylate form of SKI-O-592. Cevidoplenib and SKI-O-592 inhibits BCR-mediated survival, proliferation, and differentiation of B cells. And SKI-O-592 potently inhibits multiple kinases with IC₅₀s of 6.2 nM (Syk), 1.859 μM (Jak2), 5.807 μM (Jak3), 0.412 μM (RET), 0.687 μM (KOR), 1.783 μM (FLT3), 16.96 μM (FGFR1), 5.662 μM (FGFR3), and 0.709 μM (Pyk2), respectively .

HY-155178

Antiproliferative agent-34	EGFR	Cancer
Antiproliferative agent-34 (Compound A14) is a multi-target kinase inhibitor, with an IC₅₀ of 177 nM and 1567 nM for EGFR L858R/T790M and EGFR WT. Antiproliferative agent-34 also inhibits JAK2, ROS1, FLT3, FLT4, PDGFRα with IC₅₀ of 30.93, 106.90, 108.00, 226.60, 42.53 nM. Antiproliferative agent-34 inhibits H1975 and HCC827 cells proliferation with IC₅₀ values below 40 nM under normoxic condition, and the anti-proliferation potency achieves 4–6-fold improvement (IC₅₀ values < 10 nM) under hypoxic condition .

Pacritinib-d4
Pacritinib-d₈ (SB1518-d₈) is the deuterium labeled Pacritinib (HY-16379). Pacritinib (SB1518) is a potent inhibitor of both wild-type *JAK2* (IC₅₀=23 nM) and JAK2 ^V617F mutant (IC₅₀=19 nM). Pacritinib also inhibits *FLT3* (IC₅₀=22 nM) and its mutant FLT3 ^D835Y (IC₅₀=6 nM).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.